Economic Evaluation of Abbvie’s Regimen (Viekirax/Exviera) for Patients With Genotype 1a HCV in Greece

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.09.408
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b

BMC Gastroenterology
MedicineGastroenterology
2012English

An Economic Evaluation of the Triple HCV Treatment Regimen for G1 Naïve Patients in the Greek Health Care System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Response Prediction for Chronic HCV Genotype 4 Patients to DAAs

International Journal of Advanced Computer Science and Applications
Computer Science
2016English

Anti-Thyroid Antibodies in Patients With HCV Genotype 3a: A Pilot Study

British Microbiology Research Journal
2016English

Immunological Responses Following Administration of a Genotype 1a/1b/2/3a Quadrivalent HCV VLP Vaccine

Scientific Reports
Multidisciplinary
2018English

Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region

PLoS ONE
Multidisciplinary
2013English

HCV Genotype 1 Subtypes (1a and 1b): Similarities and Differences in Clinical Features and Therapeutic Outcome

Hepatology International
Hepatology
2014English

Economic Evaluation of Intravenous Iron Treatments in the Management of Anemia Patients in Greece

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2012English

PCN38 Economic Evaluation of Darbepoetin Alpha in the Management of Patients With Chemotherapy Induced Anemia (CIA) in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy